Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

This study has been terminated.

(Lack of recruitment and the company's decision to de-prioritize 5584 development)

Sponsor:

ClinicalTrials.gov Identifier:

NCT01991938

First Posted: November 25, 2013

Last Update Posted: January 27, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Verastem, Inc.

Study Status:	This study has been terminated.
Study Completion Date:	December 2016
Primary Completion Date:	December 2016 (Final data collection date for primary outcome measure)

Study Status:

This study has been terminated.

Study Completion Date:

December 2016

Primary Completion Date:

December 2016 (Final data collection date for primary outcome measure)